Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AKB-5169
- Development stage
- Preclinical
- Lead developer
- Akebia Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
AKB-5169 is a preclinical-stage, non-absorbed orally administered small molecule designed as a **hypoxia-inducible factor 1 (HIF-1) stabilizer/modulator** for the treatment of **inflammatory bowel disease (IBD)**. It aims to reduce inflammation and promote mucosal healing directly at the disease site while minimizing systemic exposure. Preclinical data suggest that AKB-5169 may demonstrate superior differentiation compared to standard-of-care systemic therapies in this therapeutic area. AKB-5169 originated from Janssen Pharmaceutica and was licensed to Akebia Therapeutics, which holds worldwide development rights. The drug is part of a broader portfolio of HIF-pathway modulating compounds targeting immune and digestive system diseases[1][2][3][5][9][10][11].
- Other names
- JNJ 5169JNJ5169JNJ-5169
02
Targets
PHD1 (Prolyl hydroxylase domain-containing protein 1)
Beyond the preview
Go deeper on AKB-5169.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AKB-5169.